Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 80.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 135,824 shares of the medical equipment provider's stock after acquiring an additional 60,712 shares during the period. SG Americas Securities LLC owned approximately 0.07% of Zimmer Biomet worth $15,373,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Brighton Jones LLC acquired a new stake in Zimmer Biomet in the fourth quarter valued at $204,000. Strategic Financial Concepts LLC acquired a new stake in Zimmer Biomet in the fourth quarter valued at $104,000. Sumitomo Mitsui Trust Group Inc. raised its stake in Zimmer Biomet by 4.6% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 504,362 shares of the medical equipment provider's stock valued at $53,276,000 after buying an additional 22,396 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in Zimmer Biomet by 2.0% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 22,679 shares of the medical equipment provider's stock valued at $2,396,000 after buying an additional 449 shares in the last quarter. Finally, Golden State Wealth Management LLC acquired a new stake in Zimmer Biomet in the fourth quarter valued at $73,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Wells Fargo & Company cut their price target on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Truist Financial set a $101.00 price target on Zimmer Biomet in a research note on Tuesday, May 6th. JPMorgan Chase & Co. cut their price target on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. Royal Bank of Canada cut their target price on Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Finally, Canaccord Genuity Group cut their target price on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $111.53.

Zimmer Biomet Stock Performance

ZBH traded down $2.03 during trading on Friday, reaching $91.23. The company's stock had a trading volume of 1,370,283 shares, compared to its average volume of 1,791,171. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $116.71. The company's fifty day moving average price is $96.48 and its 200-day moving average price is $103.56. The company has a market capitalization of $18.05 billion, a price-to-earnings ratio of 20.50, a price-to-earnings-growth ratio of 1.95 and a beta of 0.72. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The company had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. During the same quarter in the previous year, the company earned $1.94 EPS. The firm's revenue for the quarter was up 1.1% compared to the same quarter last year. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.05%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's dividend payout ratio is presently 21.24%.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 1,000 shares of the business's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the sale, the insider now owns 20,424 shares of the company's stock, valued at $1,940,280. The trade was a 4.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.39% of the stock is owned by corporate insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.